Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2023-12-29 Declaration of Voting R…
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Nytt antal aktier och röster i Xspray Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces a change in the number of shares and votes following the exercise of warrants (teckningsoptioner serie TO5). This directly relates to a change in the company's capital structure and share count. The filing category 'Share Issue/Capital Change' (SHA) is the most appropriate fit for reporting changes in the total number of outstanding shares due to capital activities like warrant exercise. Although it is a short announcement, the content is specific enough to classify it as SHA rather than a general RPA or RNS, as SHA is a defined category for capital changes.
2023-12-29 Swedish
New number of shares and votes in Xspray Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces a change in the number of outstanding shares and votes due to the exercise of warrants (TO5). This directly relates to changes in the company's capital structure and share count. The filing category 'Share Issue/Capital Change' (SHA) is the most appropriate fit for reporting changes in the total number of shares outstanding. Although it involves warrants being exercised (which could sometimes relate to CAP), the core announcement is the resulting change in the share count, making SHA the primary classification. The document is short and acts as an announcement, but the content is specific enough to classify beyond a general RPA or RNS.
2023-12-29 English
Xspray Pharma raises SEK 92.3 million through warrants TO5
Share Issue/Capital Change Classification · 99% confidence The document announces the outcome of exercised warrants (TO5 series), detailing the proceeds raised (SEK 92.3 million) and the intended use of funds (US launch of Dasynoc). This is a specific corporate action related to financing and capital structure changes following a rights issue. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS). The most appropriate category is Capital/Financing Update (CAP), as it details the successful completion of a financing tranche via warrants. Crucially, the document ends with an 'Attachments' section linking to a PDF, and the document length is relatively short (3887 chars). However, the content itself is the substantive announcement of the financing result, not just a notice that a report is attached. Therefore, CAP is preferred over RPA or RNS.
2023-12-01 English
Xspray Pharma tillförs 92,3 MSEK genom teckningsoptioner TO5
Share Issue/Capital Change Classification · 99% confidence The document details the outcome of a subscription period for warrants (teckningsoptioner serie TO5), resulting in the company receiving 92.3 MSEK in proceeds. This transaction involves the issuance of new shares to raise capital for business operations, specifically product launch and development. This clearly falls under the category of financing activities or capital structure changes. The most appropriate classification is 'Capital/Financing Update' (CAP). Although it is a short announcement, its primary purpose is to report the financial result of a capital raise, not just to announce that a report is forthcoming (which would be RPA/RNS).
2023-12-01 Swedish
Xspray Pharma erhåller avsiktsförklaringar från storägare och nyckelpersoner avseende teckning av TO5 i november
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement (3531 characters) detailing that Xspray Pharma has received written letters of intent (avsiktsförklaringar) from major shareholders and key personnel to subscribe for new shares via warrants (TO5) in November. This relates directly to financing activities and capital structure changes (subscription of new shares via warrants). This fits the definition of 'Capital/Financing Update' (CAP). Although it is an announcement, the core subject is the financing commitment itself, not just the publication of a larger report, making CAP more specific than RPA or RNS. The text explicitly mentions the subscription price, the period, and the potential capital raised (125.5 MSEK if fully exercised).
2023-11-09 Swedish
Xspray Pharma’s large shareholders and key individuals declare their intent to exercise TO5 warrants in November
Major Shareholding Notification Classification · 99% confidence The document announces that large shareholders and key individuals of Xspray Pharma have declared their intent to exercise TO5 warrants in November 2023. This relates to the subscription for newly issued shares, which is a capital structure change or financing activity. The text explicitly mentions the exercise of warrants and the expected gross proceeds (SEK 125.5 million), fitting the description of a Capital/Financing Update (CAP). Although it is a regulatory announcement (indicated by the final paragraph referencing EU Market Abuse Regulation), the core subject matter is the financing/capital event, making CAP the most specific fit over the general RNS fallback. The document length is short (3673 chars) and it includes an attachment link, but the content itself is the primary announcement of the financing intent, not just an announcement *about* the publication of a report, thus it is classified as CAP.
2023-11-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.